1. Patients and Families
  2. Clinical Trial Database
  3. Canadian clinical trial registry

Canadian clinical trial registry

Search results

Information is also accessible through the patient and families tab. Family friendly summaries are created and reviewed by our advocacy partners. The information is updated to the best of our knowledge but might not reflect the latest information. Note that most studies are only available at a limited number of sites, please click on ‘further information’ for details. Studies, particularly early phase trials, may also temporarily close to enrolment or not have slots available for all treatment groups. In all cases, study teams at individual C17 centres will have the most up-to-date information.

105 results found

Title
Status

 

CFZ008 - Phase 1b Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Closed

More information

CFZ008 - Phase 1b Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Go to Health Care Provider version

DiagnosisAcute Lymphoblastic LeukemiaStudy StatusClosed
PhaseI
AgeChild, Adult - (1 Year to 21 Years)RandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment Administrationintravenous (carfilzomib); Other drugs as usually administered for leukemia therapy
Last Posted Update2025-07-16
ClinicalTrials.gov #NCT02303821
International Sponsor
Amgen
Principal Investigators for Canadian Sites
CHU Ste-Justine - Dr. Henrique Bittencourt

Centres
Medical contact
Dr. Henrique Bittencourt
Dr. Monia Marzouki
Dr. Sebastien Perreault (neuro-onc)
 
Social worker/patient navigator contact
Marie-Claude Charrette
 
Clinical research contact
Marie Saint-Jacques
 

 

 

Study Description

This phase I/II trial is trying to determine how much carfilzomib (an anti-cancer drug) should be used, alone and in combination with induction chemotherapy, to treat children with acute lymphoblastic leukemia that has come back (relapsed) or is refractory to treatment. Carfilzomib is an anti-cancer medication called proteasome inhibitor and is given intravenously.

 

Inclusion Criteria
  • Age 1 year to 21 years
  • Acute lymphoblastic leukaemia that has come back (relapsed) or is refractory to treatment
  • Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

M20-429 - A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms

Closed

More information

M20-429 - A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms

Go to Health Care Provider version

DiagnosisNon-hodgkin LymphomaStudy StatusClosed
PhaseI
Age1 to 25 Years OldRandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationDrug: Epcoritamab Subcutaneous Injection (SC) Other Name: ABBV-GMAB-3013
Last Posted Update2025-07-16
ClinicalTrials.gov #NCT05206357
International Sponsor
AbbVie
Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Sarah Alexander
CHU Sainte-Justine - Dr. Henrique Bittencourt
Centres
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

Medical contact
Dr. Henrique Bittencourt
Dr. Monia Marzouki
Dr. Sebastien Perreault (neuro-onc)
 
Social worker/patient navigator contact
Marie-Claude Charrette
 
Clinical research contact
Marie Saint-Jacques
 

 

 

Study Description

The purpose of this study is to assess the safety and tolerability of the study drug epcoritamab in pediatric participants with relapsed/refractory aggressive mature B-cell neoplasms. The study drug will be given subcutaneously in 28 day cycles and participants will be followed for a minimum of 3 years after enrolling.

Inclusion Criteria
  • Participants must have Burkitt's or Burkitt-like lymphoma/leukemia, diffuse large B-cell lymphoma, or other aggressive mature B-cell lymphomas 
  • Tumour must have come back (relapsed) or progressed after previous treatment
  • Between 1-18 years of age
  • Participants must be able to be up and about at least half of their waking hours
  • Adequate organ function 

Other inclusion or exclusion criteria may apply and will be discussed with you by the clinical team

ReRAD - A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma

Closed

More information

ReRAD - A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma

Go to Health Care Provider version

DiagnosisRecurrent or Progressive Diffuse Intrinsic Pontine GliomaStudy StatusClosed
PhaseII
AgeChild - (up to 17 Years)RandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationPatients will receive 30.6 Gy or 36 Gy of a second course of radiation therapy for progressive or recurrent DIPG
Last Posted Update2025-07-16
ClinicalTrials.gov #NCT03126266
International Sponsor
University of Calgary
Principal Investigators for Canadian Sites
Alberta Children’s Hospital - Dr. Lucie Lafay-Cousin
Stollery Children’s Hospital - Dr. Bev Wilson
Children's Hospital of Eastern Ontario (CHEO) - Dr. Donna Johnston
Hamilton Health Sciences Centre, Mc Master University
BC Children’s Hospital – Dr. Juliette Hukin
Montreal Children's Hospital – Dr. Freeman
CHU Ste-Justine – Dr. Yvan Samson
CHU de Quebec – Dr. Samuele Renzi
Children's Hospital of Western Ontario – Dr. Shayna Zelcer
Janeway Hospital - Dr. Lynette Bowes
The Hospital for Sick Children - Dr. Ute Bartels
Centres
Medical contact
Dr. Victor Lewis

 

Social worker/patient navigator contact
Wendy Pelletier
Clinical research contact
Debra Rich
Medical contact
Dr. Sarah McKillop
Dr. Sunil Desai

 

 

Social worker/patient navigator contact
Danielle Sikora
 Michelle Woytiuk 
Jaime Hobbs
Clinical research contact
Amanda Perreault
Medical contact
Dr. Donna Johnston
 
Dr. Lesleigh Abbott
 
Dr. Nirav Thacker
 
Social worker/patient navigator contact
Sherley Telisma
 
Clinical research contact
Isabelle Laforest
 
Medical contact
Dr. Carol Portwine
 
Social worker/patient navigator contact
Jane Cassano 
 
Clinical research contact
Sabrina Millson
 
 
Medical contact
Rebecca Deyell

 

Social worker/patient navigator contact
Ilana Katz 

 

Clinical research contact
Hem/Onc/BMT Clinical Trials Unit

 

Medical contact
Clinical Research Unit
 
Social worker/patient navigator contact
Clinical Research Unit
 
Clinical research contact
Stephanie Badour
 
Medical contact
Dr. Henrique Bittencourt
Dr. Monia Marzouki
Dr. Sebastien Perreault (neuro-onc)
 
Social worker/patient navigator contact
Marie-Claude Charrette
 
Clinical research contact
Marie Saint-Jacques
 
Medical contact
Raoul Santiago
 
Social worker/patient navigator contact
Isabelle Audet
 
Clinical research contact
Barbara Desbiens
 

 

Medical contact
Dr. Alexandra Zorzi
Dr. Shayna Zelcer
 
Social worker/patient navigator contact
Cindy Milne Wren
Jessica Mackenzie Harris
 
Clinical research contact
Mariam Mikhail
Medical contact
Dr. Paul Moorehead
 
Social worker/patient navigator contact
Stephanie Eason
 
Clinical research contact
Bev Mitchell
 
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

 

 

Study Description

Diffuse Intrinsic Pontine Glioma (DIPG) is an aggressive brain tumour with no effective treatment and no chance of long-term survival . When this brain tumour grows back after the initial radiation therapy, it is known as progressive or recurrent DIPG.

This study will investigate how long a second treatment with radiation (re-irradiation) keeps progressive or recurrent DIPG from growing again and the overall survival of these patients. All children enrolled will be treated with re-irradiation.

Inclusion Criteria
  • The patient is 17 years of age or younger at the time of first or second relapse or progression of disease
  • The patient has no evidence of metastases on MRI of the brain and the spine
  • The patient has received radiation in the past, given to a total dose of <60 Gy
  • At least 180 days (6 months) have elapsed from the last day of primary radiation
  • Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

AC220-A-U202-ADVL1822 - A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination With Re-Induction Chemotherapy, and as a Single-Agent Continuation Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) With FLT3-ITD Mutations

Open

More information

AC220-A-U202-ADVL1822 - A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination With Re-Induction Chemotherapy, and as a Single-Agent Continuation Therapy, in Pediatric Relapsed/Refractory AML Subjects Aged 1 Month to <18 Years (and Young Adults Aged up to 21 Years) With FLT3-ITD Mutations

Go to Health Care Provider version

DiagnosisAcute Myeloid Leukemia, AMLStudy StatusOpen
PhaseI/II
AgeChild, Adult - (1 Month to 21 Years)RandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationQuizartinib by mouth; other drugs are given as usually administered for leukemia therapy.
Last Posted Update2025-07-16
ClinicalTrials.gov #NCT03793478
International Sponsor
Daiichi Sankyo, Inc.
Principal Investigators for Canadian Sites
Montreal Children's Hospital – Dr. Sharon Abish
The Hospital for Sick Children - Dr. Jim Whitlock
BC Children's Hospital - Dr. Rebecca Deyell
Centres
Medical contact
Clinical Research Unit
 
Social worker/patient navigator contact
Clinical Research Unit
 
Clinical research contact
Stephanie Badour
 
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

Medical contact
Rebecca Deyell

 

Social worker/patient navigator contact
Ilana Katz 

 

Clinical research contact
Hem/Onc/BMT Clinical Trials Unit

 

 

 

Study Description

This study is to find the appropriate dose as well as to assess the safety and effectiveness of a drug called quizartinib for children with relapsed or refractory acute myeloid leukemia (AML) with a certain mutation called FLT3-ITD. Quizartinib is a drug designed to specifically block the FLT3 protein when it is abnormal in a leukemia cell.

Inclusion Criteria
  • Children 1 month to 21 years of age
  • Acute myeloid leukemia that has come back or is not responding to current treatment
  • Presence of the FLT3-ITD mutation in the leukemia
  • Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.

 

APAL2020D - A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML

Open

More information

APAL2020D - A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Children With Relapsed AML

Go to Health Care Provider version

DiagnosisAcute Myeloid LeukemiaStudy StatusOpen
PhaseIII
Age29 Days to 21 YearsRandomisationYES
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationDrug: Fludarabine - Intravenous (IV) infusion Drug: Cytarabine - Intravenous (IV) infusion Drug: Gemtuzumab Ozogamicin - Intravenous (IV) infusion Drug: Azacitidine - Intravenous (IV) infusion or subcutaneous injection Experimental Arm Drug: Venetoclax - Orally via tablet or powder suspension
Last Posted Update2025-07-16
ClinicalTrials.gov #NCT05183035
International Sponsor
LLS PedAL Initiative, LLC
Principal Investigators for Canadian Sites
BC Children's Hospital - Dr. Rebecca Deyell
CancerCare Manitoba
IWK Health Center
Children's Hospital of Eastern Ontario (CHEO)
SickKids - The Hospital for Sick Children - Dr. Jim Whitlock
Centres
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

Medical contact
Rebecca Deyell

 

Social worker/patient navigator contact
Ilana Katz 

 

Clinical research contact
Hem/Onc/BMT Clinical Trials Unit

 

Medical contact
Dr. Magimairajan Vanan
Social worker/patient navigator contact
Rhéanne Bisson
 
Clinical research contact
Rebekah Hiebert
Megan Ridler
Kathy Hjalmarsson

 

 

Medical contact
Dr. Craig Erker
Dr. Conrad Fernandez 
Dr. Ketan Kulkarni 
 
Social worker/patient navigator contact
Rhonda Brophy
 
Clinical research contact
Tina Bocking
 
Medical contact
Dr. Donna Johnston
 
Dr. Lesleigh Abbott
 
Dr. Nirav Thacker
 
Social worker/patient navigator contact
Sherley Telisma
 
Clinical research contact
Isabelle Laforest
 

 

 

Study Description

This study evaluates if the addition of a drug called venetoclax to chemotherapy improves survival of relapsed acute myeloid leukemia (AML). This is a trial for children, adolescents and young adults with 2nd relapsed AML or 1st relapsed AML unable to receive additional anthracycline containing chemotherapy.

Inclusion Criteria
  • Participants must be ≥ 29 days of age and ≤ 21 years of age at enrollment.
  • Participants must have previously been enrolled on APAL2020SC prior to starting this study 
  • Participants or their parents/guardians must sign a consent form to be on this study
  • Participants must be children, adolescents, and young adults with relapsed acute myeloid leukemia (AML) with either 2nd relapsed AML or 1st relapsed AML unable to receive additional anthracycline containing chemotherapy. 
  • AML must not have a mutation called FLT3/internal tandem duplication (ITD)
  • Participants must have fully recovered from all prior anti-cancer therapy and must meet the minimum durations from prior anti-cancer directed therapy prior to start of protocol treatment. These timelines will be discussed with you by the study team. 
  • Participants must have an adequate performance status (daily activity level)
  • Adequate organ function of the kidneys, liver and heart

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team






     
  •  
  •  
  •  

PLAT-07 - Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-07: A Phase 1/2 Study of CD22-Specific CAR T Cells for CD22+ Leukemia or Lymphoma

Open

More information

PLAT-07 - Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-07: A Phase 1/2 Study of CD22-Specific CAR T Cells for CD22+ Leukemia or Lymphoma

Go to Health Care Provider version

DiagnosisCD22+ Leukemia or LymphomaStudy StatusOpen
PhaseI/II
Ageup to 30 YearsRandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationBiological: SCRI-CAR22v2 (Single infusion)
Last Posted Update2025-07-16
ClinicalTrials.gov #NCT04571138
International Sponsor
Seattle Children's Hospital
Principal Investigators for Canadian Sites
BC Children's Hospital - Dr. Amanda Li
Centres
Medical contact
Rebecca Deyell

 

Social worker/patient navigator contact
Ilana Katz 

 

Clinical research contact
Hem/Onc/BMT Clinical Trials Unit

 

 

 

Study Description

This study is for people with leukemia or lymphoma that didn’t get better with treatment or came back. Doctors will take the patient’s own immune cells (T cells), change them in the lab to help them find and kill cancer, and give them back to the patient. These are called CAR T cells.

The CAR T cells in this study look for a cancer marker called CD22. 

  • The first part of the study checks if the treatment is safe and finds the right dose.
  • The second part checks if this treatment is effective.
Inclusion Criteria
  • Participants must be 30 years or younger 
  • Participants must have leukemia or lymphoma that has come back or not responded to treatment 
  • Participants must be able to have blood collected or have enough T cells stored 
  • Must be up and about at least 50% of waking hours
  • Recovered from side effects of past treatments if using new T cells
  • Must meet organ function and blood test requirements
  • If participant can have children, a strong birth control must be used until 12 months after treatment 
  • Participant or legal guardian must sign consent form

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team. 

EndRAD (ONC1701) - A Phase II Pilot Trial to Estimate Survival After a Non-total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed With B-acute Lymphoblastic Leukemia (ALL) Who Are Pre-allogeneic Hematopoietic Cell Transplantation (HCT) Next-generation-sequence (NGS) Minimal Residual Disease (MRD) Negative

Open

More information

EndRAD (ONC1701) - A Phase II Pilot Trial to Estimate Survival After a Non-total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed With B-acute Lymphoblastic Leukemia (ALL) Who Are Pre-allogeneic Hematopoietic Cell Transplantation (HCT) Next-generation-sequence (NGS) Minimal Residual Disease (MRD) Negative

Go to Health Care Provider version

DiagnosisB-cell Acute Lymphoblastic LeukemiaStudy StatusOpen
PhaseII
Age1 Year to 25 YearsRandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationDrug: Myeloablative allogeneic HCT with a non-TBI conditioning regimen. Myeloablative study regimen will consist of busulfan, fludarabine and thiotepa.
Last Posted Update2025-07-16
ClinicalTrials.gov #NCT03509961
International Sponsor
Pediatric Transplantation & Cellular Therapy Consortium
Principal Investigators for Canadian Sites
Alberta Children's Hospital - Dr. Tony Truong
Centres
Medical contact
Dr. Victor Lewis

 

Social worker/patient navigator contact
Wendy Pelletier
Clinical research contact
Debra Rich

 

 

Study Description

This study is for children and young people with B-cell acute lymphoblastic leukemia (B-ALL) who need a bone marrow transplant.

Before the transplant, doctors will check the bone marrow using a very sensitive test to see if there are any tiny signs of leukemia left.

  • If no leukemia is found, the patient may get a gentler treatment before the transplant (called non-TBI conditioning).

  • If some leukemia is still found, the patient will get the usual treatment their hospital gives. These patients will still be part of the study so doctors can learn from their care.

The goal is to see if the gentler treatment is safe for patients with a lower chance of the leukemia coming back.

Inclusion Criteria

For Treatment Arm: 

  • Must be between 1 and 25 years old
  • Has B-ALL and is in first or second remission
  • Test shows no leukemia before transplant (NGS-MRD negative)
  • Has not had a stem cell transplant before
  • Must be up and about at least 60% of participants waking hours and well enough for transplant
  • Can give consent (or has a guardian who can)
  • Meets all organ function requirements 

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team.

OPTIMISE - ARM A - Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Open

More information

OPTIMISE - ARM A - Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Go to Health Care Provider version

DiagnosisRelapsed/Refractory Solid tumour (+ lymphoma) or CNS tumourStudy StatusOpen
PhaseI/II
Age0 Years to 21 YearsRandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationArm A | Drug: Irinotecan (IV), Temozolomide (Oral), Paxalisib (Oral)
Last Posted Update2025-07-11
ClinicalTrials.gov #NCT06208657
International Sponsor
Australian & New Zealand Children's Haematology/Oncology Group
Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Daniel Morgenstern
Centres
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

 

 

Study Description

 

 This study is eligible for STEP-1 funding. Find more information here. 

 

Both Australia (Zero Childhood Cancer) and Canada (PROFYLE) have programs that study the genetics of childhood cancers to help find better treatments. OPTIMISE is a study that matches patients with new treatments based on their tumor’s genetic profile. The study tests different treatment combinations to find the most effective ones for children with cancer.

The information below is for Treatment Arm A which will be combining a drug called paxalisib with conventional chemotherapy in children and adolescents with cancer.

Inclusion Criteria
  • Patients must have a cancer that hasn't responded to regular treatment or doesn't have a good treatment option
  • They must be under 21 years old. Patients 21 years and older may be considered with approval if they have a childhood-type cancer
  • They need to be part of a precision medicine study (like PROFYLE, ZERO or equivalent)
  • Must meet tumor measurement requirements
  • Must be up and about at least 50% of patients waking hours
  • Patients need to be fully recovered from past treatments
  • Must meet all organ function and bloodwork requirements
  • Must agree to allowable methods of birth control. Participants may not be pregnant on this study. 
  • Must agree to sign a consent form and to the study activities

 

Arm A specific: 

  • Cohort A1: Patients must have disease that can seen on a scan.
  • Cohort A2: Patients must have a mutation in the appropriate genetic pathway (called PI3K/AKT/mTOR) which will be confirmed by a tumour DNA testing
  • Cohort A3: Patients can join if their tumour shows any genetic change in the pathway above, even if not from the specific mutations from Cohort A2
  • Adequate cardiac function

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team.